TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Tyra Biosciences, Inc. (TYRA) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | D+ (1.6) | C (2.5) | C- (1.9) | C+ (2.6) | C (2.2) |
| 2026-11-08 | C+ (2.5) | D+ (1.7) | C (2.5) | C- (2.1) | C+ (2.6) | C (2.3) |
| 2026-11-01 | C+ (2.5) | D+ (1.7) | C (2.4) | D+ (1.8) | C+ (2.7) | C (2.2) |
| 2026-10-25 | C+ (2.5) | D+ (1.7) | C (2.4) | C- (1.9) | C+ (2.6) | C (2.2) |
| 2026-10-18 | C+ (2.5) | D+ (1.7) | C (2.4) | C- (1.9) | C+ (2.6) | C (2.2) |